Le Lézard
Classified in: Health
Subjects: PDT, PER

Quthero Welcomes Dr. Omar Ibrahimi as Chief Medical Director


TORONTO, April 2, 2024 /PRNewswire/ -- Quthero, a pioneering biotech company renowned for its unique Q-peptide platform technology, welcomes Omar Ibrahimi, MD, PhD, a world-renowned dermatologist, to the Quthero team as their Chief Medical Director. Quthero's groundbreaking technology facilitates the complete regeneration of a patient's natural tissue with minimal scarring.

Quthero proudly announces that renowned dermatologist, Dr. Omar Ibrahimi, joins the team as Chief Medical Director.

Dr. Ibrahimi, a Harvard-trained, board-certified dermatologist, is the founder and medical director of the Connecticut Skin Institute with over 20 years of experience. Dr. Ibrahimi is accredited by the American Academy of Dermatology, the American Society for Lasers in Surgery and Medicine, the American Society for Dermatologic Surgery and the American College of Mohs Surgery. He is well-known nationally and internationally, having been an invited speaker at numerous national meetings, and has written extensively about Mohs Surgery, Laser and Cosmetic Procedures for leading medical journals. Dr. Ibrahimi has been responsible for unveiling and optimizing many of the latest cosmetic procedures that have been introduced in recent years and his practice is among the first to receive the latest innovations in aesthetic dermatology. Dr. Ibrahimi has served as Quthero's Clinical Advisor and was one of two physicians conducting Quthero's split-face clinical trial on the use of Quthero's post-procedure products on patients undergoing radiofrequency microneedling or laser face resurfacing.

"It is a privilege and a great honor to have Dr. Ibrahimi join Quthero to lead the launch of Quthero's post-procedure products as a Chief Medical Director. Dr. Ibrahimi's knowledge and experience is indispensable. We are grateful for the trust he put into our company by leading our clinical studies and distributing the products and look forward to many more results to come," said Milica Radisic, PhD, President and CEO of Quthero. 

"The Q-peptide platform holds tremendous potential for us in regenerative medicine. While we are starting with applications of this novel peptide on the skin, it has the potential to transform many fields of medicine. It's a favorite product of my patients and staff," said Dr. Ibrahimi.

Quthero has harnessed the potential of its patented Q-peptide platform technology to develop multiple applications. Proven to accelerate healing, reduce redness and bruising, and prevent scarring post-cosmetic procedures, Quthero's products are available for direct purchase on their website www.quthero.com or through participating physicians.

About Quthero:
Quthero is discovering and developing innovative applications for tissue regeneration utilizing their patented Q-peptide technology that are effective, safe and cost competitive. To learn more, visit Quthero.com.

About Dr. Ibrahimi:
Dr. Omar A. Ibrahimi is the founding and medical director of the Connecticut Skin Institute. He is a board-certified Dermatologist who has completed advanced fellowship training in Skin Cancer, Laser and Cosmetic Surgery. Dr. Ibrahimi has trained at the most prestigious medical institutions in the country. He is one of the foremost physicians in the diagnosis and treatment of all types of skin cancer, as well as medical and cosmetic issues involving the skin. He has been honored as a Castle-Connolly Top Doctor since 2016 for his outstanding patient care. For more information: https://ctskindoc.com/omar-ibrahimi-md-phd-dermatologist/

SOURCE Quthero, Inc.


These press releases may also interest you

at 18:00
Lifeist Wellness Inc. ("Lifeist" or the "Company") , a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, today announced that its Board of Directors has approved...

at 17:44
This National Volunteer Month, while many organizations honored local volunteers who generously gave of their time and talents all year long, one community also saluted its own. Meet Maplewood at Strawberry Hill?the vibrant senior living community...

at 17:31
DelveInsight's Medical Dynamometers Market Insights report provides the current and forecast market analysis, individual leading medical dynamometers companies' market shares, challenges, medical dynamometers market drivers, barriers, trends, and...

at 17:31
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), announces the results of matters voted on at the Company's annual general and special meeting of shareholders (the "Meeting") held earlier today....

at 17:20
Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") today announced that it has filed notice with NASDAQ of the Company's intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of Dissolution...

at 17:15
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on April 30, 2024. One individual was...



News published on and distributed by: